If you saw the CagriSema headline and want to know how much weight people lost, here is the short answer. In REDEFINE 9, a phase 3b trial of adults without diabetes, people on either CagriSema dose level averaged 20.7% and 21.0% weight loss after 68 weeks, counting only those who finished. The placebo group averaged 2.0%. The Medical Xpress news summary describes CagriSema as an investigational treatment, so treat these as trial results.
Quick facts, as of 2026-11-16
| Item | Detail |
|---|---|
| Trial name | REDEFINE 9 |
| Study type | Phase 3b, multicentre, randomized, double-blind, placebo-controlled |
| Length | 68 weeks |
| Participants | 309 adults without diabetes, with obesity or overweight plus a weight-related condition |
| Sites | 24 sites in Canada, France, Germany, the UK and the US |
| Arms | CagriSema 1.7/1.7 mg (104 people), CagriSema 1.0/1.0 mg (103), placebo (102) |
| Counseling | Nutrition and activity counseling in all arms |
| Drug status | Described as investigational (Medical Xpress, 16 November 2026) |
| Published in | The Lancet Diabetes & Endocrinology, 2026 (Wharton S et al.) |
What did REDEFINE 9 test?
The Lancet Diabetes & Endocrinology paper is the full report. The Medical Xpress summary, published 16 November 2026 with content provided by The Lancet, describes it this way. The trial compared a weekly combination of cagrilintide and semaglutide, called CagriSema, against placebo over 68 weeks.
The 309 adults were 77% women, with a mean age of 48 and a mean starting weight of 109.5 kg. Participants were randomly assigned to one of three arms. Everyone, in every arm, received nutrition and activity counseling. That shared counseling matters when you read the weight numbers, because each arm started from the same lifestyle support.
How much weight did people lose in REDEFINE 9?
These are the results the Medical Xpress summary reports from the paper.
| Measure at 68 weeks | CagriSema 1.7/1.7 mg | CagriSema 1.0/1.0 mg | Placebo |
|---|---|---|---|
| Mean weight loss, completers | 20.7% | 21.0% | 2.0% |
| Mean weight loss, all randomized | 19.4% | 18.6% | 4.6% |
| Lost 5% or more (estimated) | 95.1% | 96.3% | 33.4% |
| Lost 20% or more | 51.3% | 48.3% | 2.7% |
| Waist change | -17.2 cm | -17.5 cm | -3.6 cm |
Why are there two weight loss numbers for each group?
Each arm has two averages because the trial counted people in two ways. The completers number counts only people who reached week 68. The all-randomized number counts everyone assigned to a group, including people who stopped early.
Read the completers figure as the result for people who finished. Read the all-randomized figure as the result for the whole group the trial started with. The 5% and 20% rows show the share of people who reached those weight-loss marks. The 5% row is an estimate, as the summary labels it.
What did the authors say?
The authors, quoted in the Medical Xpress summary, say CagriSema “led to substantial weight loss.” They also say “CagriSema is an investigational treatment and further trials with larger, more diverse populations are needed.” They suggest the two dose levels may allow more individualised treatment.
What should you take from this?
The numbers describe what happened in this one trial, with its counseling in all arms and its 309 adults. If you're weighing a weight-loss medicine, bring these numbers to your prescriber and ask what they mean for your situation. For a broader view of the options that are already approved, the weight loss medications and programs overview is a good starting point.
Common mix-ups to avoid
REDEFINE 1 is a separate trial
REDEFINE 1 also tested CagriSema, but it's a different study with a different dose. The PubMed record for REDEFINE 1 describes it as a phase 3a, 68-week trial, registered as NCT05567796. Its blood pressure results are reported in the journal Hypertension (2026). Systolic blood pressure changed by -10.9 mm Hg on CagriSema versus -2.8 mm Hg on placebo.
| Feature | REDEFINE 9 | REDEFINE 1 |
|---|---|---|
| Phase | 3b | 3a |
| Length | 68 weeks | 68 weeks |
| Participants | 309 adults without diabetes | 3,417 randomized, adults without diabetes |
| CagriSema dose | 1.7/1.7 mg and 1.0/1.0 mg | 2.4 mg/2.4 mg |
| What the report covers | Weight and waist change | Blood pressure |
| Where reported | Medical Xpress summary of the Lancet paper | PubMed, Hypertension (2026) |
Eloralintide plus tirzepatide is a different study
A separate conference report covers eloralintide plus tirzepatide. That combination was tested in adults with overweight or obesity and type 2 diabetes. It was presented as an oral session at ObesityWeek 2026 on 15 November 2026, and Endocrinology Advisor reported it on 16 November 2026. Because the people and the study length differ, its numbers don't line up with REDEFINE 9's.
Other REDEFINE numbers
This page covers REDEFINE 9 and REDEFINE 1. For any other REDEFINE number, search the trial name or number on ClinicalTrials.gov registry to see that study's record.
Key dates
| Date | What it refers to |
|---|---|
| 15 November 2026 | ObesityWeek 2026 oral session on eloralintide plus tirzepatide |
| 16 November 2026 | Medical Xpress summary of the REDEFINE 9 results, with content provided by The Lancet |
| 2026 | Year listed for the Lancet Diabetes & Endocrinology paper and the REDEFINE 1 blood pressure report |
What to ask before you decide anything
- Ask your prescriber whether CagriSema is available to you, since Medical Xpress describes it as investigational.
- Ask your prescriber or pharmacist which approved weight-loss options fit your situation. The ozempic vs wegovy vs zepbound comparison lays out approved options side by side.
- Read the safety section of the full paper, or ask your prescriber to walk you through what the trial reported on side effects.
- Check the trial's record on ClinicalTrials.gov for its sponsor and registration details.
By TotalCareMedical.com Health Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.